Cargando…
Low-dose nivolumab can be effective in non-small cell lung cancer: alternative option for financial toxicity
OBJECTIVES: Nivolumab is used at 3 mg/kg or fixed doses of 240 mg every 2 weeks. There was no dose–response/toxicity relationship of nivolumab. This study evaluated the efficacy of low-dose nivolumab as an alternative to the financial toxicity of standard-dose nivolumab in treatment of non-small cel...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6069908/ https://www.ncbi.nlm.nih.gov/pubmed/30094065 http://dx.doi.org/10.1136/esmoopen-2018-000332 |